ClinicalTrials.gg
CompletedNCT00722137Updated Jul 12, 2018Results posted

Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma

A Phase 3 interventional study of Rituximab 375 mg/m^2 and Cyclophosphamide 750 mg/m^2 in Mantle Cell Lymphoma, sponsored by Millennium Pharmaceuticals, Inc.. Completed at 150 sites in 29 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-12.

Sponsored by Millennium Pharmaceuticals, Inc. (part of Takeda) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
487
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 50 studies testing bortezomib in Lymphoma, Mantle-Cell — none open to participants now, none under way, none of them phase 3. Bortezomib · Lymphoma, Mantle-Cell.

Enrollment
Largest of 47
487 · median 36
Started
2008
with 3 others
Phase 3
2 of 50
none open now
Registered
30th of 50
by date
Lead sponsor
2 of 50
Millennium Pharmaceuticals, Inc.

Among the 50 studies testing bortezomib in Lymphoma, Mantle-Cell, this one has the largest enrollment of the 47 interventional ones that give a count, is one of 4 that started in 2008, is one of 2 in phase 3, and was the 30th registered.

Lymphoma, Mantle-Cell

1,221 studies on the registry are indexed under Lymphoma, Mantle-Cell; 155 are open to participants now.

Browse Lymphoma, Mantle-Cell studies →

Open to participants now

None of the 50 studies testing bortezomib in Lymphoma, Mantle-Cell is open now. The open studies under Lymphoma, Mantle-Cell, anywhere →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 125 Lymphoma, Mantle-Cell studies recruiting now, 92 (74%) set no upper age limit and 12 (10%) stop at 75 or younger; 14 take children under 18; 2 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 50 studies testing bortezomib in Lymphoma, Mantle-Cell as a file.
02

Study summary

This is a randomized, open-label, multicenter, prospective study to compare the efficacy and safety of the combination of VcR-CAP to that of R-CHOP in participants who have newly diagnosed mantle cell lymphoma grade II, III or IV and who are ineligible to undergo bone marrow transplantation.

Read the detailed description

The drug being tested in this study were combination of VcR-CAP and R-CHOP. Combination of VcR-CAP and R-CHOP is being tested to treat people who had mantle cell lymphoma (MCL).

The study enrolled 487 patients. Participants were randomly assigned (by chance, like flipping a coin) to one of the two treatment groups in a 1:1 ratio:

Treatment Group A (VcR-CAP) Treatment Group B (R-CHOP)

The study included a screening phase, a treatment phase, a short-term follow-up phase, and a long-term follow-up phase. The screening phase was up to 28 days (56 days for bone marrow evaluation) prior to randomization.

This multi-center trial was conducted worldwide. The total study duration from randomization of the first patient until the last progression-free survival (PFS) event required for the final analysis was expected to be approximately 42 months (24 months for enrollment and 18 months for follow-up) and survival follow-up every 12 weeks until death.

03

Conditions studied

  • Mantle Cell Lymphoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female patients 18 years or older (the patient must be at least the legal age limit to be able to give within the jurisdiction the study is taking place)
  • Diagnosis of mantle cell lymphoma MCL (Stage II, III or IV) as evidenced by lymph node histology and either expression of cyclin D1 (in association with CD20 and CD5) or evidence of t(11;14) translocation, such as by cytogenetics, fluorescent in situ hybridization (FISH) or polymerase chain reaction (PCR). Patients with a diagnosis of Stage I MCL will not be permitted to enter study.

    • Paraffin embedded tissue block (preferably of lymph node origin) must be sent to the central laboratory for confirmation of MCL diagnosis prior to randomization. In China, a paraffin embedded lymph node biopsy tissue block must be sent for central confirmation of sample adequacy, prior to randomization
  • At least 1 measurable site of disease
  • No prior therapies for MCL
  • Not eligible for bone marrow transplantation as assessed by the treating physician (e.g., age or the presence of co-morbid conditions that may have a negative impact on the tolerability to transplantation).
  • ECOG status ≤2
  • (ANC) ≥1500 cells/µL,
  • ≥100,000 cells/µL or ≥75,000 cells/µL if thrombocytopenia is considered by the investigator to be secondary to MCL (e.g., due to bone marrow infiltration or sequestration from splenomegaly).
  • ≤3 x (ULN)
  • Aspartate transaminase ≤3 x ULN
  • Total ≤1.5 x ULN,
  • Calculated ≥20 mL/min.
  • Female patients must be post menopausal for at least 1 year (must not have had a natural menses for at least 12 months), surgically sterile, or practicing an effective method of (e.g., prescription oral contraceptives, contraceptive injections, intrauterine device, double-barrier method, contraceptive patch, male partner sterilization) and have a negative serum βHCG or urine pregnancy test at screening. They must also be prepared to continue birth control measures for at least 6 months after terminating treatment.
  • Male patients must agree to use an acceptable method of contraception (for themselves or female partners as listed above) for the duration of the study.
  • All patients (or their legally acceptable representatives) must have signed an informed consent document indicating that they understand the purpose of and procedures required for the study and are willing to participate in the study.
  • In order to participate in the pharmacogenomics component of this study, patients (or their legally acceptable representative) must have signed the informed consent form for pharmacogenomics research indicating willingness to participate in the pharmacogenomics component of the study. Acquisition of tumor sample collections is required for all patients (where available); all other sample collections are optional

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with VELCADE
  • Prior antineoplastic (including unconjugated therapeutic antibodies), experimental or radiation therapy, radioimmunoconjugates or toxin immunoconjugates for the treatment of MCL. In the event that a patient has received doxorubicin for the treatment of any condition, other than MCL, the maximum dose and exposure received prior to entry into this study should not exceed 150 mg/m2.

    • short course (maximum of 10 days, not exceeding 100 mg/day) prednisone or equivalent are allowed to treat symptoms in patients with advanced disease who enter the screening phase and are waiting to be randomized.
  • Major surgery (at the discretion of the treating physician and in consultation with the sponsor's medical monitor) within 2 weeks before randomization
  • Peripheral neuropathy or neuropathic pain of Grade 2 or worse (as per the investigators assessment)
  • Diagnosed or treated for a other than MCL within 1 year of randomization, or who were previously diagnosed with a malignancy other than MCL and have any radiographic or biochemical marker evidence of malignancy. Patients with completely resected basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancy are not excluded.
  • Active systemic infection requiring treatment and patients with known diagnosis of HIV or active (carriers of hepatitis B are permitted to enter study)
  • History of allergic reaction attributable to compounds containing boron, mannitol, or hydroxybenzoates
  • Known anaphylaxis or immunoglobulin E (IgE)-mediated to murine proteins or to any component of rituximab including polysorbate 80 and sodium citrate dihydrate
  • Female or male patients of who will not use adequate during the course of the study.
  • Serious medical (e.g., pericardial disease, cardiac failure [; NYHA Class III or IV, Attachment 12 or ; LVEF \<50%], active peptic ulceration, uncontrolled diabetes mellitus, or acute diffuse infiltrative pulmonary disease), or psychiatric illness likely to interfere with participation in this clinical study
  • Concurrent treatment with another agent.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
487 participants (actual)

Study arms

  • Active comparator
    R-CHOP

    Rituximab 375 mg/m\^2, Cyclophosphamide 750 mg/m\^2, Doxorubicin 50 mg/m\^2, Vincristine 1.4 mg/m\^2, and Prednisone 100 mg/m\^2

    Drug: Rituximab 375 mg/m^2 · Drug: Cyclophosphamide 750 mg/m^2 · Drug: Doxorubicin 50 mg/m^2 · Drug: Prednisone 100 mg/m^2 · Drug: Vincristine 1.4 mg/m^2

  • Experimental
    VcR-CAP

    Rituximab 375 mg/m\^2, Cyclophosphamide 750 mg/m\^2, Doxorubicin 50 mg/m\^2, VELCADE 1.3 mg/m\^2, and Prednisone 100 mg/m\^2

    Drug: Rituximab 375 mg/m^2 · Drug: Cyclophosphamide 750 mg/m^2 · Drug: Doxorubicin 50 mg/m^2 · Drug: VELCADE 1.3 mg/m^2 · Drug: Prednisone 100 mg/m^2

Interventions

  • DrugRituximab 375 mg/m^2

    Drug page: Rituximab

    Intravenous rituximab 375 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles.

  • DrugCyclophosphamide 750 mg/m^2

    Drug page: Cyclophosphamide

    Intravenous cyclophosphamide 750 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles

  • DrugDoxorubicin 50 mg/m^2

    Drug page: Doxorubicin

    Intravenous doxorubicin 50 mg/m\^2 on Day 1 of a 21-day (3 week) cycle for 6 cycles

  • DrugVELCADE 1.3 mg/m^2

    Drug page: Bortezomib

    Intravenous VELCADE 1.3 mg/m\^2 on Days 1,4,8, and 11of a 21-day (3 week) cycle for 6 cycles

  • DrugPrednisone 100 mg/m^2

    Drug page: Prednisone

    Oral prednisone 100 mg/m\^2 on Day 1 to Day 5 of a 21-day (3 week) cycle for 6 cycles

  • DrugVincristine 1.4 mg/m^2

    Drug page: Vincristine

    Intravenous vincristine 1.4 mg/m\^2 on Day 1of a 21-day (3 week) cycle for 6 cycles. Maximum of 2 mg. Participants could receive 8 cycles if a response was initially documented at the Cycle 6 assessment.

06

What researchers measure

Primary outcomes

  1. Progression Free Survival (PFS)

    PFS was defined as the interval between the date of randomization and the date of progressive disease (PD) or death, whichever occurred first. PD was based on the assessment of an Independent Review Committee.

    Time frame: Median duration of follow-up of 40 months

Secondary outcomes

  1. Time to Progression (TTP)

    Time to progression was defined as the duration from the date of randomization until the date of first documented evidence of progressive disease (PD) or date of relapse for subjects who experienced complete response (CR) or complete response, unconfirmed (CRu). PD and response were based on the assessment of an Independent Review Committee.

    Time frame: Median duration of follow-up of 40 months

  2. Duration of Response

    The duration of treatment response was defined as the time from the date of the first response to the date of PD or death due to PD for those participants with a best response of CR, CRu, or PR as determined by the Independent Review Committee. The duration of response for complete responders was defined as the time from the date of the first response to the date of PD or death due to PD for those participants with a best response of CR or CRu verified by bone marrow and lactate dehydrogenase (LDH).

    Time frame: Median duration of follow-up of 40 months

  3. Time to Next Anti-lymphoma Treatment (TTNT)

    The time to next anti-lymphomatreatment was measured from the date of initiation of study treatment as per protocol to the start date of new anti-lymphoma treatment. Death due to disease progression prior to subsequent therapy was considered as an event. Otherwise, time to next anti lymphoma treatment was censored at the date of death or the last date known to be alive.

    Time frame: : Median duration of follow-up of 40 months

  4. Treatment-free Interval (TFI)

    The TFI was defined as the duration from the date of last dose plus 1 day to the start date of the new treatment. Death due to disease progression prior to subsequent therapy was considered as an event. Otherwise, treatment-free interval was censored at the date of death or the last date known to be alive.

    Time frame: Median duration of follow-up of 40 months

  5. Overall Response Rate (ORR)

    ORR was defined as complete response (CR) + complete response, unconfirmed (CRu) + partial response (PR) as determined by the Independent Review Committee. Response assessment was carried out every 6 weeks for 18 weeks; thereafter, every 8 weeks until PD/initiation of alternate therapy/withdrawal from study/death.

    Time frame: Median duration of follow-up of 40 months

  6. Overall Complete Response (CR + CRu)

    Overall complete response was defined as the number of participants with complete response (CR) and those with unconfirmed complete response (CRu). Response assessment was carried out every 6 weeks for 18 weeks; thereafter, every 8 weeks until PD/initiation of alternate therapy/withdrawal from study/death.

    Time frame: Median duration of follow-up of 40 months

  7. Overall Survival (OS)

    OS was measured from the date of randomization to the date of the participant's death. If the participant was alive or the vital status was unknown, OS was censored at the date that the subject was last known to be alive.

    Time frame: Median duration of follow-up of 40 months

  8. 18-Month Survival

    18-month survival was defined as the estimated probability of survival at 18 months (Kaplan-Meier estimate).

    Time frame: Up to month 18 from the time of randomization

  9. Overall Survival (OS) in Long Term Follow-up Period

    OS was measured from the date of randomization to the date of the participant's death. If the participant was alive or the vital status was unknown, OS was censored at the date that the subject was last known to be alive.

    Time frame: Up to 107.4 months

  10. Number of Participants Experiencing an Adverse Event (AE)

    An AE was defined as any untoward medical occurrence associated with the use of a drug, whether or not considered drug related. AEs were collected from the first dose of study drug through 30 days after the last dose of study drug. Treatment was administered for up to 8 cycles (24 weeks) and AEs were collected for up to 30 days following the last dose of study drug.

    Time frame: Up to 107.4 months

07

Results

Posted Nov 17, 2014

Participant flow

A total of 487 participants were randomized from 128 centers in 28 countries from 22 May 2008 to 17 June 2017; 244 to the R-CHOP treatment group and 243 to the VcR-CAP treatment group. Of the 487 randomized participants, 242 in the R-CHOP group and 240 in the VcR-CAP group received at least 1 dose of study drug.

Participant flow — Overall Study
MilestoneR-CHOPVcR-CAP
Started244243
Completed199195
Not completed4548
Withdrew: Overt disease progression54
Withdrew: Adverse event1721
Withdrew: Death127
Withdrew: Withdrawal by subject69
Withdrew: Other reason unknown34
Withdrew: Randomized but not treated23

Outcome measures

PrimaryProgression Free Survival (PFS)

PFS was defined as the interval between the date of randomization and the date of progressive disease (PD) or death, whichever occurred first. PD was based on the assessment of an Independent Review Committee.

Time frame:
Median duration of follow-up of 40 months
Reported as:
Median · Days
Progression Free Survival (PFS)
DaysR-CHOPVcR-CAP
Progression Free Survival (PFS)437.0 (365.0 to 513.0)751.0 (604.0 to 969.0)
Statistical analysis
  • R-CHOP vs VcR-CAP · Log Rank · p = <0.001 · Hazard ratio (hr): 0.63 · 95% CI 0.50 to 0.79Hazards ratio estimate is based on a Cox´s model stratified by IPI risk and stage of disease. A hazard ratio \< 1 indicates an advantage for VcR-CAP.
SecondaryTime to Progression (TTP)

Time to progression was defined as the duration from the date of randomization until the date of first documented evidence of progressive disease (PD) or date of relapse for subjects who experienced complete response (CR) or complete response, unconfirmed (CRu). PD and response were based on the assessment of an Independent Review Committee.

Time frame:
Median duration of follow-up of 40 months
Reported as:
Median · Days
Time to Progression (TTP)
DaysR-CHOPVcR-CAP
Time to Progression (TTP)490.0 (417.0 to 550.0)929.0 (696.0 to 1245.0)
Statistical analysis
  • R-CHOP vs VcR-CAP · Log Rank · p = <0.001 · Hazard ratio (hr): 0.58 · 95% CI 0.45 to 0.74Hazards ratio estimate is based on a Cox´s model stratified by IPI risk and stage of disease. A hazard ratio \< 1 indicates an advantage for VcR-CAP.
SecondaryDuration of Response

The duration of treatment response was defined as the time from the date of the first response to the date of PD or death due to PD for those participants with a best response of CR, CRu, or PR as determined by the Independent Review Committee. The duration of response for complete responders was defined as the time from the date of the first response to the date of PD or death due to PD for those participants with a best response of CR or CRu verified by bone marrow and lactate dehydrogenase (LDH).

Time frame:
Median duration of follow-up of 40 months
Reported as:
Median · Days
Duration of Response
DaysR-CHOPVcR-CAP
Duration of response459.0 (379.0 to 518.0)1110.0 (813.0 to 1320.0)
Duration for Complete responders563.0 (486.0 to 738.0)1282.0 (933.0 to 1602.0)
SecondaryTime to Next Anti-lymphoma Treatment (TTNT)

The time to next anti-lymphomatreatment was measured from the date of initiation of study treatment as per protocol to the start date of new anti-lymphoma treatment. Death due to disease progression prior to subsequent therapy was considered as an event. Otherwise, time to next anti lymphoma treatment was censored at the date of death or the last date known to be alive.

Time frame:
: Median duration of follow-up of 40 months
Reported as:
Median · Days
Time to Next Anti-lymphoma Treatment (TTNT)
DaysR-CHOPVcR-CAP
Time to Next Anti-lymphoma Treatment (TTNT)756.0 (674.0 to 837.0)1353.0 (1180.0 to NA)
Statistical analysis
  • R-CHOP vs VcR-CAP · Log Rank · p = <0.001 · Hazard ratio (hr): 0.50 · 95% CI 0.38 to 0.65Hazards ratio estimate is based on a Cox´s model stratified by IPI risk and stage of disease. A hazard ratio \< 1 indicates an advantage for VcR-CAP.
SecondaryTreatment-free Interval (TFI)

The TFI was defined as the duration from the date of last dose plus 1 day to the start date of the new treatment. Death due to disease progression prior to subsequent therapy was considered as an event. Otherwise, treatment-free interval was censored at the date of death or the last date known to be alive.

Time frame:
Median duration of follow-up of 40 months
Reported as:
Median · Days
Treatment-free Interval (TFI)
DaysR-CHOPVcR-CAP
Treatment-free Interval (TFI)624.0 (542.0 to 693.0)1236.0 (1023.0 to NA)
Statistical analysis
  • R-CHOP vs VcR-CAP · Log Rank · p = =0.001 · Hazard ratio (hr): 0.50 · 95% CI 0.38 to 0.65
SecondaryOverall Response Rate (ORR)

ORR was defined as complete response (CR) + complete response, unconfirmed (CRu) + partial response (PR) as determined by the Independent Review Committee. Response assessment was carried out every 6 weeks for 18 weeks; thereafter, every 8 weeks until PD/initiation of alternate therapy/withdrawal from study/death.

Time frame:
Median duration of follow-up of 40 months
Reported as:
Number · Participants
Overall Response Rate (ORR)
ParticipantsR-CHOPVcR-CAP
Overall Response Rate (ORR)204211
Statistical analysis
  • R-CHOP vs VcR-CAP · Cochran-Mantel-Haenszel Chi-Square · p = 0.275 · Odds ratio (or): 1.428 · 95% CI 0.749 to 2.722Mantel-Haenszel estimate of the common odds ratio for stratified tables is used, with IPI risk and Stage of Disease as stratification factors. An odds ratio (OR) \> 1 indicates an advantage for VcR-CAP.
SecondaryOverall Complete Response (CR + CRu)

Overall complete response was defined as the number of participants with complete response (CR) and those with unconfirmed complete response (CRu). Response assessment was carried out every 6 weeks for 18 weeks; thereafter, every 8 weeks until PD/initiation of alternate therapy/withdrawal from study/death.

Time frame:
Median duration of follow-up of 40 months
Reported as:
Number · Participants
Overall Complete Response (CR + CRu)
ParticipantsR-CHOPVcR-CAP
Overall complete response95122
CR79106
CRu1616
Statistical analysis
  • R-CHOP vs VcR-CAP · Cochran-Mantel-Haenszel Chi-Square · p = <0.007 · Odds ratio (or): 1.688 · 95% CI 1.148 to 2.481Mantel-Haenszel estimate of the common odds ratio for stratified tables is used, with IPI risk and Stage of Disease as stratification factors. An odds ratio (OR) \> 1 indicates an advantage for VcR-CAP.
SecondaryOverall Survival (OS)

OS was measured from the date of randomization to the date of the participant's death. If the participant was alive or the vital status was unknown, OS was censored at the date that the subject was last known to be alive.

Time frame:
Median duration of follow-up of 40 months
Reported as:
Median · Days
Overall Survival (OS)
DaysR-CHOPVcR-CAP
Overall Survival (OS)1714.0 (1436.0 to NA)NA (1704.0 to NA)
Statistical analysis
  • R-CHOP vs VcR-CAP · Log Rank · p = 0.173 · Hazard ratio (hr): 0.80 · 95% CI 0.59 to 1.10Hazards ratio estimate is based on a Cox´s model stratified by IPI risk and stage of disease. A hazard ratio \< 1 indicates an advantage for VcR-CAP.
Secondary18-Month Survival

18-month survival was defined as the estimated probability of survival at 18 months (Kaplan-Meier estimate).

Time frame:
Up to month 18 from the time of randomization
Reported as:
Mean · Percentage of Participants
18-Month Survival
Percentage of ParticipantsR-CHOPVcR-CAP
18-Month Survival83.8 (78.4 to 87.9)84.9 (79.6 to 88.9)
SecondaryOverall Survival (OS) in Long Term Follow-up Period

OS was measured from the date of randomization to the date of the participant's death. If the participant was alive or the vital status was unknown, OS was censored at the date that the subject was last known to be alive.

Time frame:
Up to 107.4 months
Reported as:
Median · Days
Overall Survival (OS) in Long Term Follow-up Period
DaysR-CHOPVcR-CAP
Overall Survival (OS) in Long Term Follow-up Period1695.0 (1436.0 to 2098.0)2760.0 (2172.0 to NA)
SecondaryNumber of Participants Experiencing an Adverse Event (AE)

An AE was defined as any untoward medical occurrence associated with the use of a drug, whether or not considered drug related. AEs were collected from the first dose of study drug through 30 days after the last dose of study drug. Treatment was administered for up to 8 cycles (24 weeks) and AEs were collected for up to 30 days following the last dose of study drug.

Time frame:
Up to 107.4 months
Reported as:
Number · Participants
Number of Participants Experiencing an Adverse Event (AE)
ParticipantsR-CHOPVcR-CAP
Number of Participants Experiencing an Adverse Event (AE)239240

Adverse events

Collected over Up to 107.4 months. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
R-CHOP—72/242 (29.8%)187/242 (77.3%)
VcR-CAP—91/240 (37.9%)185/240 (77.1%)
Most frequent serious events
Showing 10 of 138
Most frequent serious events
EventR-CHOPVcR-CAP
Febrile neutropeniaBlood and lymphatic system disorders20/24226/240
PneumoniaInfections and infestations7/24219/240
NeutropeniaBlood and lymphatic system disorders13/24212/240
PyrexiaGeneral disorders4/24210/240
ThrombocytopeniaBlood and lymphatic system disorders1/2428/240
LeukopeniaBlood and lymphatic system disorders3/2426/240
AnaemiaBlood and lymphatic system disorders5/2424/240
DyspnoeaRespiratory, thoracic and mediastinal disorders5/2422/240
SepsisInfections and infestations1/2424/240
Pulmonary embolismRespiratory, thoracic and mediastinal disorders1/2424/240
Most frequent other events
Showing 10 of 20
Most frequent other events
EventR-CHOPVcR-CAP
NauseaGastrointestinal disorders33/24259/240
CoughRespiratory, thoracic and mediastinal disorders20/24249/240
AlopeciaSkin and subcutaneous tissue disorders33/24233/240
InsomniaPsychiatric disorders18/24227/240
Abdominal distensionGastrointestinal disorders5/24222/240
Pain in extremityMusculoskeletal and connective tissue disorders5/24220/240
HyperglycaemiaMetabolism and nutrition disorders20/24218/240
Neuropathy peripheralNervous system disorders19/24219/240
Abdominal painGastrointestinal disorders9/24218/240
Abdominal pain upperGastrointestinal disorders11/24216/240

Baseline characteristics

The population consisted of all randomized participants.

Age, Continuous
Age, Continuous(Years)R-CHOPVcR-CAPTotal
Mean64.4 ± 8.7864.2 ± 9.6864.3 ± 9.23
Sex: Female, Male
Sex: Female, Male(Participants)R-CHOPVcR-CAPTotal
Female6265127
Male182178360
Race (NIH/OMB)
Race (NIH/OMB)(Participants)R-CHOPVcR-CAPTotal
American Indian or Alaska Native000
Asian6888156
Native Hawaiian or Other Pacific Islander000
Black or African American033
White172151323
More than one race415
Unknown or Not Reported000
Region of Enrollment
Region of Enrollment(Participants)R-CHOPVcR-CAPTotal
Belgium101626
Poland91019
Czech Republic5914
Spain8614
Hungary5813
Romania9413
Austria6410
Italy639
Germany718
Portugal347
France123
Canada617
United States257
Russia574299
China346195
Ukraine181634
Brazil91322
Thailand91019
Japan11718
India9312
Israel527
Tunisia336
Turkey516
Colombia235
Korea, Republic Of235
Chile123
Singapore123
Taiwan, Province Of China123
08

Study locations

150 sites
  • St. Francis Hosptial and Medical Center
    Hartford, Connecticut 06105, United States
  • Center for Cancer Care at Goshen Hospital
    Goshen, Indiana 46526, United States
  • Sinai Hospital
    Baltimore, Maryland 21215, United States
  • Capitol Comp. Cancer Center
    Jefferson City, Missouri 65109, United States
  • Nebraska Cancer Specialists
    Omaha, Nebraska 68114, United States
  • Hematology-Oncology Associates of Northern NJ
    Morristown, New Jersey 07960, United States
  • Legacy Pharma Research
    Bismarck, North Dakota 58501, United States
  • Division of Hematology and Oncology Vanderbilt University
    Nashville, Tennessee 37232, United States
  • Cancer Outreach Associates, PC
    Abingdon, Virginia 24211, United States
  • St.Johanns Spital/Landeskrankenhaus Salzburg
    Salzburg, Austria
  • Allgemeines Krankenhaus der Stadt Wien
    Wien, Austria
  • AZ Stuivenberg Oncologie/ Hematologie
    Antwerpen, Belgium
  • AZ St Jan AV
    Brugge, Belgium
  • UZ Brussel Department Medical Oncology
    Brussels, Belgium
  • UZA Hematologie, 1e verdiep
    Edegem, Belgium
  • Universitair Ziekenhuis Gent - UZ GENT, Hematologie, 9K12IE 9de verdiep- polikliniek Hematologie
    Gent, Belgium
  • UZ Leuven Gasthuisberg Hematologie
    Leuven, Belgium
  • C.H.R. Citadelle
    Liege, Belgium
  • Centre Hospitalier Universitaire
    Liege, Belgium
  • Ucl de Mont-Godinne
    Yvoir, Belgium
  • Centro de Hematologia E Hemoterapia - Unicamp
    Campinas, Brazil
  • Fundacao Hospital Amaral Carvalho
    Jau, Brazil
  • Hospital Nossa Senhora da Conceicao
    Porto Alegre, Brazil
  • Hospital Sao Lucas Puc-Rs
    Porto Alegre, Brazil
  • Inca - Instituto Nacional Do Cancêr
    Rio de Janeiro, Brazil
  • Centro de Estudos de Hematologia E Oncologia Da Fmabc
    Sao Paulo, Brazil
  • Fundacao Pio XII - Hospital de Cancer de Barretos
    Sao Paulo, Brazil
  • Hospital Ac Camargo
    Sao Paulo, Brazil
  • Hospital Alemao Oswaldo Cruz
    Sao Paulo, Brazil
  • Hospital das Clínicas da Faculdade de Medicina da USP
    Sao Paulo, Brazil
  • Santa Casa de Misericórida de São Paulo
    Sao Paulo, Brazil
  • Cross Cancer Institute
    Edmonton, Alberta, Canada
  • University Health Network, Princess Margaret Hospital
    Toronto, Ontario, Canada
  • Hospital Clinico Universidad Catolica de Chile
    Santiago, Chile
  • Hospital Del Salvador
    Santiago, Chile
  • Instituto Nacional Del Cancer
    Santiago, Chile
  • Sun Yat-sen University Cancer Center
    Guangzhou, Guangdong, China
  • West China Hospital, Sichuan University
    Chengdu, Sichuan, China
  • Zhejiang University First Hospital
    Hangzhou, Zhejiang, China
  • Beijing Cancer Hospital
    Beijing, China
  • Cancer Institute & Cancer Hospital, CAMS&PUMC
    Beijing, China
  • Peking University Third Hospital
    Beijing, China
  • Cancer hospital, Fudan University
    Shanghai, China
  • Ruijin Hospital
    Shanghai, China
  • Tianjin Medical University Cancer Hospital and Institute
    Tianjin, China
  • Clinica Reina Sofia
    Bogota, Colombia
  • Hospital Pablo Tobon Uribe
    Medellin, Colombia
  • Hospital Universitario San Vicente de Paul
    Medellin, Colombia
  • Interni hematoonkoligicka klinika
    Brno, Czechia
  • Interni klinika - Oddeleni klin. hematologie Fakultni nemocnice Hradec Kralove
    Hradec Kralove, Czechia
  • Oddeleni klinicke hematologie, Fakultni nemocnice Kralovske Vinohrady
    Praha, Czechia
  • Vivantes Klinikum Neukölln Klinik für Innere Medizin Hämatologie und Onkologie
    Berlin, Germany
  • Vivantes Klinikum Spandau Klinik für Innere Medizin - Hämatologie, Onkologie und Gastroenterologie
    Berlin, Germany
  • Städt. Kliniken Frankfurt-Hoechst Med. Klinik II - Hämatologie und Onkologie
    Frankfurt, Germany
  • Tumorklinik SANAFONTIS Alpine GmbH
    Freiburg, Germany
  • Wilhelm-Anton-Hospital Goch gGmbH Klinik für Hämatologie und internistische Onkologie
    Goch, Germany
  • Klinikum Lippe-Lemgo Med. Klinik II - Hämatologie und Onkologie
    Lemgo, Germany
  • Johannes-Gutenberg-Universität Mainz III. Med. Klinik
    Mainz, Germany
  • Mutterhaus der Borromäerinnen Med. Klinik I
    Trier, Germany
  • Schwarzwald-Baar-Kliniken Innere Med. II
    Villingen, Germany
  • Debreceni Egyetem Orvos- es Egeszsegtudomanyi Centrum, III. sz. Belgyogyaszati Klinika
    Debrecen, Hungary
  • Petz Aladár Kórház, II. Belgyógyászat
    Győr, Hungary
  • Kaposi Mor Megyei Korhaz, Belgyogyaszat
    Kaposvar, Hungary
  • Apollo Hospital and Research Foundation, Apollo Hospitals
    Hyderabad 500033, Andhra Pradesh, India
  • Sir Ganga Ram Hospital
    New Delhi- 110060, Delhi, India
  • Kidwai Memorial Institute of Oncology
    Bangalore 560 029, Karnataka, India
  • Regional Cancer Centre, Medical Oncology
    Thiruvananthapuram, Kerala-695011, India
  • Jehangir Hospital
    Pune-411002, Maharashtra, India
  • Apollo Speciality Hospital, Chennai
    Chennai-600035, Tamil Nadu, India
  • Netaji Subash Chanda Bose Cancer Research Institute
    Kolkata- 700016, West Bengal, India
  • Rambam Medical Center-Hematology department
    Haifa, Israel
  • Hadassah Medical Center - Hematology department
    Jerusalem, Israel
  • Rabin Medical Center, Beilinson Campus
    Petach Tiqva, Israel
  • Sheba Medical Center
    Ramat-Gan, Israel
  • Kaplan Medical Center - Hematology Institute
    Rechovot, Israel
  • Azienda Ospedaliera Universitaria di Bologna Policlinico S.Orsola-Malpighi Dipartimento di Ematologia e Scienze Oncologiche "L. e A. Seragnoli"
    Bologna, Italy
  • Spedali Civili di Brescia
    Brescia, Italy
  • Dipartimento di Oncologia ed Ematologia Università di Modena e Reggio Emilia
    Modena, Italy
  • AZIENDA OSPEDALIERA UNIVERSITARIA POLICLINICO TOR VERGATA DIPARTIMENTO DI MEDICINA U.O.C. Ematologia
    Roma, Italy
  • Azienda Ospedaliera San Giovanni Battista "Molinette" Struttura Complessa Ematologia 2
    Torino, Italy
  • University Malaya Medical Centre
    Kuala Lumpur, Malaysia
  • Gleneagles Medical Centre
    Pulau Pinang, Malaysia
  • Hopital Du 20 Aout 1953
    Casablanca, Morocco
  • Centre D'oncologie Al Azhar
    Rabat, Morocco
  • Institut National D'oncologie
    Rabat, Morocco
  • National Kidney and Transplant Institute
    Quezon City, Philippines
  • St Lukes Medical Center
    Quezon City, Philippines
  • Szpital Morski im. PCK w Gdyni Gdynskie Centrum Onkologii Oddzial Chemioterapii
    Gdynia, Poland
  • Klinika Hematologii Uniwersytetu Medycznego w Lodzi
    Lodz, Poland
  • "Katedra i Klinika Hematologii i Chorob Rozrostowych Ukladu Krwiotworczego
    Poznan, Poland
  • Klinika Hematologii Nowotworow Krwi i Transplantacji Szpiku Akademii Medycznej we Wroclawiu
    Wroclaw, Poland
  • Hospital Sao Marcos
    Braga, Portugal
  • Hospitais da Universidade de Coimbra
    Coimbra, Portugal
  • Hospital de Santa Maria
    Lisboa, Portugal
  • Instituto Portugues de Oncologia
    Porto, Portugal
  • Spitalul Judetean de Urgenta "Dr. Constantin Opris", Hematologie
    Baia Mare, Romania
  • Institutul Clinic Fundeni, Hematologie
    Bucuresti, Romania
  • Spitalul Clinic Coltea, Clinica Hematologie
    Bucuresti, Romania
  • Spitalul Clinic Universitar de Urgenta Bucuresti, Hematologie
    Bucuresti, Romania
  • Spitalul Clinic Judetean de Urgenta "Sf. Spiridon" Iasi, Oncologie Medicala
    Iasi, Romania

Showing the first 100 of 150 sites across 29 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Robak T, Jin J, Pylypenko H, Verhoef G, Siritanaratkul N, Drach J, Raderer M, Mayer J, Pereira J, Tumyan G, Okamoto R, Nakahara S, Hu P, Appiani C, Nemat S, Cavalli F; LYM-3002 investigators. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol. 2018 Nov;19(11):1449-1458. doi: 10.1016/S1470-2045(18)30685-5. Epub 2018 Oct 19. PubMed 30348538 ↗
  • Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Pereira J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H, Cavalli F. Association between bortezomib dose intensity and overall survival in mantle cell lymphoma patients on frontline VR-CAP in the phase 3 LYM-3002 study. Leuk Lymphoma. 2019 Jan;60(1):172-179. doi: 10.1080/10428194.2017.1321750. Epub 2017 Jun 5. PubMed 28583031 ↗
  • Verhoef G, Robak T, Huang H, Pylypenko H, Siritanaratkul N, Pereira J, Drach J, Mayer J, Okamoto R, Pei L, Rooney B, Cakana A, van de Velde H, Cavalli F. Association between quality of response and outcomes in patients with newly diagnosed mantle cell lymphoma receiving VR-CAP versus R-CHOP in the phase 3 LYM-3002 study. Haematologica. 2017 May;102(5):895-902. doi: 10.3324/haematol.2016.152496. Epub 2017 Feb 9. PubMed 28183846 ↗
  • Robak T, Huang H, Jin J, Zhu J, Liu T, Samoilova O, Pylypenko H, Verhoef G, Siritanaratkul N, Osmanov E, Alexeeva J, Pereira J, Drach J, Mayer J, Hong X, Okamoto R, Pei L, Rooney B, van de Velde H, Cavalli F; LYM-3002 Investigators. Bortezomib-based therapy for newly diagnosed mantle-cell lymphoma. N Engl J Med. 2015 Mar 5;372(10):944-53. doi: 10.1056/NEJMoa1412096. PubMed 25738670 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2008 to primary completion in Jan 2014, 68 months.

Results were first posted in Nov 2014, 10 months after primary completion. A results delay was requested in Feb 2013.

Of 27 phase 3 interventional studies under Lymphoma, Mantle-Cell, half reached primary completion within 97 months of starting (the median), counting those still running; a quarter within 68. This study's 68 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 23, 2008
First posted
Jul 25, 2008
StartActual
May 1, 2008
Primary completionActual
Jan 1, 2014
CompletionActual
Jun 17, 2017
Results delay requested
Feb 1, 2013
Results first posted
Nov 17, 2014
Last update
Jul 12, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 12, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT00722137
Responsible party
Sponsor
First posted
Jul 25, 2008
Start date
May 1, 2008
Primary completion
Jan 1, 2014
Completion
Jun 17, 2017
Results posted
Nov 17, 2014
Last update
Jul 12, 2018

Study contacts

Medical Director Clinical Science
study director · Takeda

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bortezomib

Start the discussion